Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week

• Published in: Journal of the American College of Cardiology Vol. 82; no. 22; p. 2152
• Main Authors: Devesa, Ana, Ibanez, Borja, Malick, Waqas A, Tinuoye, Elizabeth O, Bustamante, Jessica, Peyra, Carlos, Rosenson, Robert S, Bhatt, Deepak L, Stone, Gregg W, Fuster, Valentin
• Format: Journal Article
• Language: English
• Published: United States 28.11.2023
• Subjects: Atherosclerosis - epidemiology; Atherosclerosis - prevention & control; Cardiovascular Diseases - prevention & control; Cholesterol, LDL; Humans; Primary Prevention; Risk Factors; Young Adult; primary prevention; cardiovascular disease; subclinical atherosclerosis; young adults
• ISSN: 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2023.09.817

There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young individuals (<40 years) are unknown. The randomized controlled PRECAD (Prevent Coronary Artery Disease) trial has been developed to assess the potential benefit of an aggressive control of CVRF in otherwise healthy young adults. The hypothesis of PRECAD is that in subjects aged 20 to 39 years without known CVD, maintaining low-density lipoprotein-cholesterol <70 mg/dL and strict control of blood pressure and glucose will prevent the onset of atherosclerosis and/or its progression. The primary endpoint will be the change in total atherosclerosis burden, a surrogate for CVD.